FDA approves a second Alzheimer's drug that can modestly slow disease

Posted
The approval of Eli Lilly's Kisunla provides a new option for patients in the early stages of the incurable, memory-destroying ailment.(Image credit: AP)

Continue reading at NPR:Health »